Device beats drugs for atrial fib

A Johnson & Johnson unit released study data yesterday showing that its catheter-based system might be more effective than drugs are at resolving heart arrhythmias. The company's Biosense Webster unit is hoping to gain FDA approval to market the device for the treatment of atrial fibrillation, making it the first approved device to treat the condition. AtriCure , Boston Scientific, Medtronic and St. Jude Medical all have competing devices, but none have received FDA approval for the condition to date. Report


Suggested Articles

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Private equity player Ampersand Capital Partners is backing another CDMO, this one targeted at sterile injectables.

How much are lawsuits hurting J&J's brand? The New Jersey drugmaker has lost half a billion dollars in brand value over the past year, a report says.